Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD-496 CAR-T therapy in advanced NKG2DL+/CLDN18.2+ solid tumors
NCT05583201Phase 1Recruiting
- Start
- Oct 2022
- Primary completion
- Jun 2024
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of KD-496 in gastric cancer (GC), pancreatic cancer (PC) and solid tumor. Primary endpoint: Treatment-Emergent Adverse Events at 3 months. Started Oct 2022; status: recruiting.
02
Drugs
KD-496
03
Conditions
gastric cancer (GC)pancreatic cancer (PC)solid tumor
Beyond the preview
Go deeper on NCT05583201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05583201.